The findings arrive amid a global surge in prescribing of incretin-based therapies, the class of drugs that includes semaglutide, the active ingredient in Ozempic and Wegovy, and tirzepatide, marketed as Mounjaro and Zepbound. Both agents mimic gut-derived hormones that regulate appetite and blood sugar, and both have transformed the treatment of obesity and diabetes. But until now, clinicians have lacked a rigorous, quantitative answer to a deceptively simple question: when a patient on one drug switches to the other, which dose is the equivalent? The new study offers a model-based answer that its authors say can support individualized treatment decisions where direct head-to-head evidence does not exist.

Led by Carlos E. Builes-Montaño of Hospital Pablo Tobón Uribe and the University of Antioquia in Medellín, Colombia, together with colleagues at Novo Nordisk, the research team assembled arm-level data from the SUSTAIN, STEP, SURPASS and SURMOUNT clinical trial programs. In total, 48 treatment arms comprising 16,524 participants were analyzed. Fifteen trials contributed data on semaglutide, spanning weekly doses from 0.5 to 7.2 milligrams, while eight trials informed the tirzepatide analysis at weekly doses of 5, 10 and 15 milligrams. Treatment durations ranged from 26 to 104 weeks, and the trial populations were broadly comparable: mean baseline age of roughly 55 years, nearly balanced sex distribution, baseline HbA1c around 7.8 percent, and mean body mass index between 33 and 34 kilograms per square meter.

The researchers deployed two complementary statistical approaches. First, they used generalized additive models, or GAMs, to trace the continuous relationship between weekly dose and percentage of body weight change for each drug. Rather than forcing the data into a rigid equation, GAMs use penalized regression splines fitted via restricted maximum likelihood to allow flexible, data-driven curves. To anchor the curves at a physiologically plausible baseline, the team inserted pseudo-observations of zero weight change at zero dose, stabilizing the models near the lower boundary of the dose range. Second, they fitted a Bayesian hierarchical model that incorporated drug-specific smooth dose effects, treatment duration as a covariate, and a study-level random intercept to account for differences between trials. The models were estimated with Hamiltonian Monte Carlo across four chains of 4,000 iterations each, with convergence confirmed using stringent diagnostic thresholds.

The two drugs both displayed nonlinear dose–response relationships, meaning the first increments of dose buy the most weight loss, while each additional step upward yields progressively smaller gains. For semaglutide, median weight loss rose from roughly 5 to 6 percent at 1.0 milligram per week to about 10 percent at 2.4 milligrams, with further reductions at the higher 7.2-milligram dose. Tirzepatide showed a clear gradient across its 5-to-15-milligram range, with the largest reductions at the highest dose. In both cases, the variability in response widened at higher doses, reflecting genuine heterogeneity in how patients respond to these therapies.

The centerpiece of the analysis was a probabilistic test of clinical equivalence across prespecified dose pairs. The team defined equivalence as a difference in predicted weight change of no more than 2 percentage points, a margin chosen because such differences are unlikely to alter real-world clinical decision-making. Using the Bayesian framework, they calculated the posterior probability that each semaglutide–tirzepatide dose pairing fell within that margin. Two combinations stood out: semaglutide 2.4 milligrams versus tirzepatide 10 milligrams showed a 99.4 percent probability of equivalence, and semaglutide 7.2 milligrams versus tirzepatide 15 milligrams showed 94.8 percent. By contrast, comparisons pairing semaglutide 1.0 milligram against tirzepatide 10 or 15 milligrams produced near-zero equivalence probabilities, confirming that low-dose semaglutide simply cannot match the weight-loss power of higher-dose tirzepatide.

Perhaps the most striking conclusion is that equivalence is driven by dose rather than drug identity. Semaglutide at 2.4 milligrams is pharmacodynamically comparable to tirzepatide at 10 milligrams, and semaglutide at 7.2 milligrams approximates tirzepatide at 15. In practical terms, a patient forced to switch drugs, whether because of supply shortages, insurance coverage, cost or side effects, may now have an evidence-informed basis for selecting a dose of the replacement that preserves their weight-loss trajectory. The authors caution, however, that pharmacodynamic equivalence should not be read as blanket therapeutic interchangeability, since tolerability profiles, patient preference and prior treatment response all remain central to treatment selection.

To translate the models into bedside decisions, the researchers simulated treatment intensification scenarios, asking what happens when patients on a given regimen either escalate their dose or switch to the competing drug. For patients taking semaglutide 1.0 milligram, both escalation to 2.4 milligrams and a switch to tirzepatide 5 milligrams produced a high probability of improved weight loss, but dose escalation within the same drug carried a substantially higher probability of achieving an additional 2 or more percentage points of weight loss, suggesting that optimizing the current therapy is preferable when it is tolerated. The calculus reversed at the higher end of the dose spectrum: in patients already receiving tirzepatide 10 milligrams, switching to semaglutide 7.2 milligrams produced a larger expected incremental benefit than escalating to tirzepatide 15 milligrams, with a higher probability of a clinically meaningful gain. In selected patients, cross-drug switching may outperform within-drug titration.

The shapes of the two dose–response curves carry their own clinical implications. Tirzepatide, a dual agonist acting on both the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, delivered larger incremental effects at lower doses, meaning patients starting tirzepatide may see faster early weight reduction. Semaglutide, meanwhile, maintained incremental benefit across an extended dose range, allowing continued titration in patients who tolerate the drug well and need additional weight loss. For both agents, the attenuation of benefit at higher doses signals diminishing returns, reinforcing the need to weigh expected benefit against injection burden, cost and individual tolerability.

The study is not without limitations, and the authors are explicit about them. The analysis relied on aggregated arm-level data rather than individual participant records, which prevented adjustment for patient-level factors such as comorbidities, concomitant medications and background glucose-lowering regimens. Variability in trial design and clinical management across the two drug programs may have introduced residual confounding, although the hierarchical model accounted for between-trial heterogeneity through random intercepts and duration adjustment. Estimates involving semaglutide 7.2 milligrams rest on a single trial and should be considered exploratory until additional data accumulate. Adverse events and discontinuation rates were extracted but not formally modeled due to inconsistent reporting across trials. And critically, the analysis focused exclusively on weight loss, leaving glycemic outcomes, cardiovascular endpoints and safety outside its scope, so the findings must be integrated with broader clinical evidence rather than replace it.

Sensitivity analyses bolstered the core conclusions. When the equivalence margin was widened to 4 or 5 percentage points, posterior probabilities of equivalence rose as expected, but the relative ranking of dose pairs remained unchanged, with the semaglutide 2.4 versus tirzepatide 10 and semaglutide 7.2 versus tirzepatide 15 pairings consistently on top. Excluding the semaglutide 7.2-milligram arm from the model left the dose–response curves for lower doses essentially untouched, indicating the results are robust to the single most uncertain data point.

The only direct head-to-head trial of these two drugs, SURMOUNT-5, was conducted in people with obesity who did not have type 2 diabetes and compared maximum tolerated doses rather than the full clinically relevant range. That gap left clinicians managing diabetes without clear guidance on dose equivalence, a gap this model-based synthesis now helps to close. The approach, the authors argue, complements rather than replaces head-to-head trials, and provides a template for probabilistic comparison of drugs when randomized comparisons are impractical or unavailable.

As demand for incretin therapies continues to climb and shortages, cost pressures and formulary restrictions force prescribing changes around the world, tools that quantify what one dose means in terms of another are likely to become increasingly valuable. The message from this analysis is at once reassuring and sobering: the drugs are more alike than their marketing suggests, but only when the dose is right, and no amount of drug switching can compensate for a dose that was never equivalent to begin with. Future work incorporating individual-level data and broader clinical endpoints, the authors say, will be needed to refine these estimates and confirm that dose-driven equivalence holds across the full diversity of patients treated in routine care.

The advent of IBTs marks an unprecedented shift in obesity management paradigms. These agents operate by modulating incretin hormone pathways, influencing appetite regulation, insulin secretion, and glucose homeostasis. Despite their transformative impact on weight reduction, the therapies are not devoid of risks, necessitating refined clinical protocols to mitigate adverse effects and maximize therapeutic gains. As these medications become more widespread, healthcare providers face the formidable challenge of balancing efficacy with the maintenance of patients’ nutritional integrity and psychological well-being.

Central to the consensus is the role of medical nutritional therapy (MNT), a critical adjunct to pharmacotherapeutics. Delivered by registered dietitians, MNT encompasses tailored dietary guidance that ensures adequate protein, micronutrient, and vitamin intake—elements essential for preserving muscle mass and preventing malnutrition amid substantial weight loss. Moreover, dietitians play a crucial role in individualized dose-scaling of obesity drugs, attenuating gastrointestinal side effects such as nausea and vomiting, which are common barriers to adherence. Importantly, the consensus emphasizes the delivery of MNT within a framework of weight-inclusive and empowering communication, recognizing that health transcends mere numerical values on the scale.

The intersection of obesity treatment and mental health forms another pillar of this comprehensive statement. While IBTs have been associated with improved psychological outcomes, patients often enter treatment with pre-existing vulnerabilities including anxiety, depression, or eating disorders. The document calls for vigilant mental health screening and monitoring by multidisciplinary teams, integrating psychological expertise to identify and address the re-emergence or exacerbation of mental health issues during the transformative process of significant weight loss. Special attention is drawn to screening for alcohol use disorders prior to GLP-1 therapy initiation due to potential pharmacodynamic interactions.

Clinicians are urged to adopt more sophisticated monitoring beyond traditional metrics such as body mass index (BMI). Emerging evidence highlights that approximately 24-30% of weight lost via IBTs corresponds to fat-free mass, predominantly muscle tissue, which may have profound implications for physical function and metabolic health, especially in older adults at heightened risk for sarcopenia. The consensus proposes a pragmatic target of an approximate 3:1 ratio favoring fat loss over lean mass depletion. To facilitate this, advanced body composition assessments, including dual-energy X-ray absorptiometry (DXA) and bioelectrical impedance analysis (BIA), alongside functional measures like handgrip strength and sit-to-stand tests, are recommended where resources permit, reinforcing the shift toward personalized and functionally oriented evaluations.

The profound importance of physical activity is underscored, with a dual focus on aerobic exercise to augment weight loss and resistance training to preserve muscular integrity. These physical interventions synergize with IBTs and MNT, preventing excessive lean mass loss while simultaneously enhancing metabolic and psychological health. The consensus highlights the necessity of patient education to foster sustainable engagement in physical activity as an integral component of obesity care pathways.

Addressing the socioeconomic disparities that permeate obesity treatment access surfaces as a critical concern. Minority ethnic communities and socioeconomically disadvantaged groups disproportionately bear the burden of obesity yet often encounter substantial barriers, including limited access to IBTs and specialist nutritional services. The consensus highlights the pernicious effects of prescription regulations favoring patients with obesity-related complications over those without, perpetuating stigma and impeding early intervention strategies. It advocates for policy reforms to expand coverage for obesity pharmacotherapies and for healthcare systems to bolster equitable access to dietitian-led MNT, potentially narrowing health disparities and improving adherence and clinical outcomes.

Despite the transformative potential of IBTs, the authors illuminate significant lacunae in research, particularly concerning the long-term nutritional, functional, and psychological impacts of these treatments. A systematic review of 417 randomized controlled trials revealed that nutritional intake and biomarker reporting are sparse, with fewer than 5% assessing bone health, micronutrient status, or physical function. Such gaps hinder comprehensive safety profiling and limit evidence-based guidelines.

To address these deficiencies, the consensus delineates an ambitious research agenda. Priorities include establishing core outcome sets for IBT trials to standardize reporting; developing malnutrition screening tools tailored to obesity contexts; rigorous evaluation of muscle function and performance metrics; and investigating optimal protein intake protocols to safeguard lean tissue during therapy. Psychological outcomes require dedicated attention, alongside innovations in dose titration to reduce gastrointestinal side effect-induced discontinuations. Pharmacokinetic safety assessments and mixed-methods studies capturing real-world patient experiences, including post-cessation and post-bariatric surgery contexts, are also urgently needed.

In concluding, the statement proclaims IBTs as emblematic of a paradigm shift in obesity treatment, necessitating the integration of dietitian-led MNT with psychological and functional support frameworks. Key therapeutic goals revolve around mitigating gastrointestinal adverse effects, preempting micronutrient deficiencies, and preserving lean mass through nutrient-dense diets enriched in protein, fiber, and fluids, complemented by targeted supplementation and resistance exercise. Emphasis is placed on holistic care that attends to identity transformation, coping mechanisms, and potential disordered-eating patterns, all grounded in respectful and inclusive patient engagement.

As obesity emerges increasingly recognized as a chronic disease requiring multifaceted management, this consensus represents a seminal step toward harmonizing pharmacological advances with nutritional science, psychological insight, and functional rehabilitation. The future of obesity care hinges on such integrative approaches, driven by patient-centered research and equitable healthcare delivery systems that transcend stigma and structural barriers.

Subject of Research: Use of incretin-based therapies in obesity treatment and associated nutritional, functional, and psychological considerations.

Article Title: New Consensus on Optimizing Obesity Drug Use Emphasizes Nutrition, Mental Health, and Functional Support

News Publication Date: 2026 (at European Congress on Obesity)

Web References: Not provided

References: Not provided

Image Credits: Not provided

Keywords: Obesity treatment, incretin-based therapies, GLP-1 receptor agonists, medical nutritional therapy, body composition, muscle mass preservation, psychological health, physical activity, socioeconomic disparities, obesity pharmacotherapy, consensus statement